As an important participant in the pharmaceutical distribution industry, Nanjing Pharmaceutical Co., Ltd. (stock code: 600713) directly serves the national medical and health industry. The company's business covers the procurement, warehousing, management and sale of pharmaceuticals and medical equipment, and is supervised by various national departments such as the Ministry of Commerce. Within the industry, Nanjing Pharmaceutical not only actively participated in industry self-regulatory organization activities, but also continued to contribute to the development of the pharmaceutical distribution field.

In terms of assets and liabilities, Nanjing Pharmaceutical's 2023 three-quarter report shows that the company's total assets increased from 31,651 billion yuan at the end of the previous year to 33.203 billion yuan, an increase of 4.90%. Total liabilities also increased, rising from $24.956 billion at the end of the previous year to $26.136 billion. Net assets increased from 6.695 billion yuan to 7.067 billion yuan, and the balance ratio declined slightly, from 78.85% to 78.72%, indicating that the company's asset structure is relatively stable.

In terms of profit, the company's revenue increased from 37.436 billion yuan in the same period last year to 40.547 billion yuan, an increase of 8.31%. Operating profit also increased from 704 million yuan to 755 million yuan. However, net profit declined from 556 million yuan to 533 million yuan, net interest rate also fell from 1.48% to 1.31%, and gross margin fell from 6.3% to 6.08%, which may reflect rising costs or operational efficiency challenges.

In terms of cash flow, net cash flow from operating activities declined, mainly due to an increase in accounts receivable. During the reporting period, the total cash inflow from operating activities was $40.964 billion, while the cash outflow subtotal was 45.448 billion yuan, resulting in a negative net cash flow of 4.484 billion yuan.

Taken together, Nanjing Pharmaceutical's overall business conditions were steady during the reporting period, the scale of assets increased, and operating income increased, but the decline in net profit and net cash flow required attention. Companies may face challenges in managing accounts receivable, which may have an impact on future cash flow conditions and profitability.

For investors, Nanjing Pharmaceuticals' steady asset growth and position in the industry are advantages worthy of recognition, but they also need to pay attention to fluctuations in its cash flow and profits. Investment decisions should comprehensively consider the company's long-term development potential and short-term cash flow pressure, and carefully evaluate its investment value.

This article only represents the judgments made by analysts themselves or analysts based on AI analysis. It cannot be used as an investment indicator, nor does it constitute any investment advice. The original purpose of this article was to help investors analyze and judge capital market data in the most intuitive and fastest way and from the most professional perspective.